76472-23-6

Basic information

• Product Name: 4-(DIMETHYLCARBAMOYLMETHYL)PHENOL
• Synonyms: 4-(DIMETHYLCARBAMOYLMETHYL)PHENOL;4-(DIMETHYLCARBAMOYLMEYTHYL)PHENOL;4-(Dimethylcarbamoylmeythyl)phenol, min. 95 %;2-(4-Hydroxyphenyl)-N,N-dimethylacetamide;BenzeneacetaMide, 4-hydroxy-N,N-diMethyl-;4-[(Dimethylcarbamoyl)methyl]phenol, 4-[2-(Dimethylamino)-2-oxoethyl]phenol
• CAS NO: 76472-23-6
• Molecular Formula: C10H13NO2
• Molecular Weight: 179.22
• Mol File: 76472-23-6.mol

Chemical Properties

• Boiling Point: 346.2°C at 760 mmHg
• Flash Point: 163.2°C
• Appearance: /
• Density: 1.133g/cm³
• Vapor Pressure: 2.92E-05mmHg at 25°C
• Refractive Index: 1.554
• CAS DataBase Reference: 4-(DIMETHYLCARBAMOYLMETHYL)PHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(DIMETHYLCARBAMOYLMETHYL)PHENOL(76472-23-6)
• EPA Substance Registry System: 4-(DIMETHYLCARBAMOYLMETHYL)PHENOL(76472-23-6)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 76472-23-6(Hazardous Substances Data)

Usage

Uses

Used in Personal Care Industry:
4-(DIMETHYLCARBAMOYLMETHYL)PHENOL is used as a preservative and antimicrobial agent for its ability to inhibit the growth of microorganisms, thereby preserving products and preventing spoilage. This makes it a common ingredient in soaps, lotions, and deodorants.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, 4-(DIMETHYLCARBAMOYLMETHYL)PHENOL is utilized in the production of medications, capitalizing on its antimicrobial properties to ensure the safety and efficacy of the final product.
Used in Cosmetics Industry:
4-(DIMETHYLCARBAMOYLMETHYL)PHENOL is used as a fragrance and flavoring agent in cosmetics, enhancing the sensory experience of the products while also providing antimicrobial benefits to maintain product integrity and consumer safety.

InChI:InChI=1/C10H13NO2/c1-11(2)10(13)7-8-3-5-9(12)6-4-8/h3-6,12H,7H2,1-2H3

Upstream product

• 14199-15-6 Methyl 4-hydroxyphenylacetate 
• 124-40-3 dimethyl amine 
• 156-38-7 4-hydroxyphenylacetate 
• 506-59-2 N,N-dimethylammonium chloride 

Relevant articles and documents

Synthetic method of hordenine hydrochloride

The invention discloses a synthetic method of hordenine hydrochloride. According to the synthetic method of hordenine hydrochloride, methyl 4-hydroxyphenylacetate and dimethylamine are taken as raw materials, a protonic solvent and a polar aprotic solvent are taken as solvents so as to obtain N,N-dimethyl-4-hydroxybenzeneacetamide; N,N-dimethyl-4-hydroxybenzeneacetamide is taken as a raw material, tetrahydrofuran is taken as a solvent, and a reducing agent and a catalyst are added so as to obtain hordenine; hydrochloric acid is added, ethanol is taken as a solvent, and hordenine hydrochloride is obtained via reaction. In the synthetic method, methyl 4-hydroxyphenylacetate is taken as a raw material, hordenine hydrochloride is obtained via two-step synthesis, the raw materials are easily available, the synthesis method is simple, amplification production is convenient to realize, production cost is low, industrialized production is convenient to realize, and market potential is high.

NOVEL TRIAZINE COMPOUNDS

The present invention relates to novel triazine compounds of formula (1), methods of their preparation, pharmaceutical compositions containing these compounds and the use of these compounds to treat proliferative disorders such as tumors and cancers and also other conditions and disorders related to or associated with dysregulation of PI3 Kinases, PI3 Kinase pathway, mTOR and/ or the mTOR pathway.

OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE

The present invention relates to compounds, which are useful for treatment and/or prevention of diabetes mellitus, diabetes mellitus complications or obesity, since the compounds have glucokinase-activating effects, and are presented in Formula (I): wherein R1 represents a carbamoyl group; R2 represents a lower alkyl group; both of X1 and X2 represent CH, or any one of X1 and X2 represents a nitrogen atom and the other represents CH; a group of represents a group selected from the group consisting of a pyridinyl, a pyrazinyl, a pyrazolyl, a thiadiazolyl, a triazolyl, an isoxazolyl and a thiazolyl group; and k is zero or 1, or relates to pharmaceutically acceptable salts thereof.